Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Exclusives

More »

For full access to this article login to GEN Select now.

Apr 28, 2014

Payers Wrestle with Reimbursement

Healthcare coverage for genomic tests in the clinic is at issue.

Payers Wrestle with Reimbursement

Medicare administrative contractors cut 2014 reimbursement rates for many molecular tests on average by 25% to 35%. [© vichie81 - Fotolia.com]

  • How private and public payers reimburse for tests is arguably the steepest hurdle to adoption of genomics by clinical practices. Yet reimbursement policies are ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.
    •  


Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »